{"disease":{"id":"portopulmonary-hypertension","name":"portopulmonary hypertension"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07314814","title":"Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Prof. Valérie Mc Lin","has_results":false},{"nct_id":"NCT02382016","title":"PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Actelion","has_results":true},{"nct_id":"NCT01517854","title":"Revatio Portal-Pulmonary Arterial Hypertension Trial","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT03309592","title":"Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Ochsner Health System","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}